Regeneron to Report Fourth Quarter and Full Year 2021 Financial and Operating Results and Host Conference Call and Webcast on

Rhea-AI Summary

Regeneron Pharmaceuticals (NASDAQ: REGN) announced its fourth quarter and full year 2021 financial results will be reported on February 4, 2022, before U.S. market opening. A conference call and webcast will occur at 8:30 AM ET on the same day. Participants can join via webcast on the company’s website.

As a leading biotechnology firm, Regeneron focuses on innovative medicines addressing serious diseases, leveraging proprietary technologies and significant research initiatives.

TARRYTOWN, N.Y., Jan. 13, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2021 financial and operating results on Friday, February 4, 2022, before the U.S. financial markets open.  The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.

Conference Call Information
Participants may access the conference call live via webcast on the 'Investors and Media' page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call.  A replay of the conference call and webcast will be archived on the Company's website for at least 30 days.

About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development, almost all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite^® technologies, such as VelocImmune^®, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.

For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.

Contact Information:
Investor Relations
Mark Hudson
914.847.3482
mark.hudson@regeneron.com

Corporate Communications
Christina Chan
914.847.8827
christina.chan@regeneron.com

View original content:https://www.prnewswire.com/news-releases/regeneron-to-report-fourth-quarter-and-full-year-2021-financial-and-operating-results-and-host-conference-call-and-webcast-on-301460682.html

SOURCE Regeneron Pharmaceuticals, Inc.

FAQ

When will Regeneron report its fourth quarter and full year 2021 results?

Regeneron will report its fourth quarter and full year 2021 financial results on February 4, 2022.

What time is Regeneron's conference call on February 4, 2022?

The conference call for Regeneron on February 4, 2022, will be held at 8:30 AM Eastern Time.

How can I access Regeneron's conference call?

You can access Regeneron's conference call via webcast on their 'Investors and Media' page or by registering for a telephone access link.

What is Regeneron's stock symbol?

Regeneron's stock symbol is REGN.

What does Regeneron Pharmaceuticals focus on?

Regeneron focuses on inventing life-transforming medicines for severe diseases through innovative biotechnology.